353 Eplerenone benefit at 30 days in high-risk subgroups in the EPHESUS trial

June 2005
European Journal of Heart Failure. Supplements;Jun2005, Vol. 4 Issue 1, p78
Academic Journal
An abstract of the article "Eplerenone Benefit at 30 days in High-Risk Subgroups in the EPHESUS Trial," by M. Aschermann and colleagues is presented.


Related Articles

  • Allocation strategy for a controlled clinical trial to assess the Expert Patient Program Cataloniaâ„¢ clinical effectiveness on diabetes. Amil, Paloma; Boix, Carme; González-Mestre, Asunción; Sala, Núria; Álamo, Maria-Dolors; Roura-Poch, Pere // International Journal of Integrated Care (IJIC);2015 Supp, Vol. 15, p1 

    Introduction: In Catalonia, self-care support is being developed through the Expert Patient Program Cataloniaâ„¢ (EPPCâ„¢) integrated from primary health care which provides specific courses (taught by a patient, an equal) to improve patients' self-care skills. Whereas there is some...

  • Lung Cancer: NAB-PACLITAXEL LINKED TO HIGHER ORR AND SUPERIOR OS IN ELDERLY. Hirsh, Vera // Oncology Exchange;Aug2012, Vol. 11 Issue 3, p24 

    The article presents abstracts of clinical trials for non-small cell lung cancer (NSCLC) including the improvement of objective response rate (ORR) from nanoparticle albumin-bound paclitaxel plus carboplatin (nab-P/C), the efficacy and safety of nab-P/C, and the analysis of symptoms of...

  • GI highlights from the literature. Aithal, Guruprasad P. // Gut;Sep2011, Vol. 60 Issue 9, p1300 

    The article presents abstracts on various medical conditions and their treatment which include the study for the efficiency and safety of telbivudine in pregnancy, the risk of malignant development in Barrett's esophagus patients, and the clinical trials for otilonium bromide in patients with...

  • 'Wishful thinking' blamed for clinical trials flops. Dickinson, James G. // Medical Marketing & Media;Aug2011, Vol. 46 Issue 8, p10 

    The article focuses on the results of a research study which confirm the association of wishful thinking on the increasing failures of clinical trials due to lack of efficacy and strategic reasons in the U.S.

  • SPIRIT IV results reinforce Xience safety and efficacy.  // Medical Device Daily;5/7/2010, Vol. 14 Issue 88, p11 

    The article deals with the results from Abbott's SPIRIT IV trial, a randomized clinical trial comparing Abbott's Xience V Everolimus Eluting Coronary Stent System and the Taxus Express2 Paclitaxel-Eluting Coronary Stent System, pubished in a 2010 issue of the "New England Journal of Medicine."

  • Flare-Ups of Gout Reduced.  // Clarendon Enterprise (TX);10/2/2008, Vol. 19 Issue 39, p7 

    The article highlights the results of a clinical trial of Arcalyst (rilonacept), an inhibitor of interluekin-1, a body protein that drives inflammation in a number of conditions including gout.

  • Late Breaking News.  // Multiple Sclerosis Journal;Sep2013 Supplement, p559 

    The article presents abstracts on multiple sclerosis (MS) including the use of natalizumab therapy in progressive multifocal leukoencephalopathy (PML) in MS patients, phase II trial on the effect of riluzole in early relapsing-remitting MS, and the association of Dnase hypersensitive sites with MS.

  • Gatorade/Miralax colonoscopy prep effective, not improved by bisacodyl.  // Hem/Onc Today;8/10/2012, Vol. 13 Issue 15, p28 

    The article discusses the findings of a blind, placebo-controlled, randomized clinical trial which revealed that effectiveness including Gatorade and Miralax to colonoscopy preparation, but was not improved by the addition of bisacodyl.

  • Positive results in Southampton-led patient trial for new asthma treatment.  // Biomedical Market Newsletter;4/21/2012, Vol. 21, p1 

    The article informs that scientists from the University of Southampton, Southampton, England and Synairgen PLC have released data from its Phase II clinical trial evaluating the effectiveness of the drug SNG001 (inhaled interferon beta) for asthma patients.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics